Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' JUDSON I' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 52 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Judson, I; Radford, JA; Harris, M; Blay, JY; van Hoesel, Q; le Cesne, A; van Oosterom, AT; Clemons, MJ; Kamby, C; Hermans, C; Whittaker, J; di Paola, ED; Verweij, J; Nielsen, S
      Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL (R)/CAELYX (R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

      EUROPEAN JOURNAL OF CANCER
    2. Verweij, J; Judson, I; van Oosterom, A
      STI571: a magic bullet?

      EUROPEAN JOURNAL OF CANCER
    3. Ng, C; Stebbing, J; Judson, I
      Cardiac metastasis from a myxoid liposarcoma

      CLINICAL ONCOLOGY
    4. van Oosterom, AT; Judson, I; Verweij, J; Stroobants, S; di Paola, ED; Dimitrijevic, S; Martens, M; Webb, A; Sciot, R; Van Glabbeke, M; Silberman, S; Nielsen, OS
      Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study

      LANCET
    5. Nielsen, OS; Judson, I; van Hoesel, Q; le Cesne, A; Keizer, HJ; Blay, JY; van Oosterom, A; Radford, JA; Svancarova, L; Krzemienlecki, K; Hermans, C; van Glabbeke, M; Oosterhuis, JW; Verweij, J
      Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

      EUROPEAN JOURNAL OF CANCER
    6. Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P
      Gene expression profiling of human colon cancer cells following inhibitionof signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone

      ONCOGENE
    7. Briasoulis, E; Judson, I; Pavlidis, N; Beale, P; Wanders, J; Groot, Y; Veerman, G; Schuessler, M; Niebch, G; Siamopoulos, K; Tzamakou, E; Rammou, D; Wolf, L; Walker, R; Hanauske, A
      Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group

      JOURNAL OF CLINICAL ONCOLOGY
    8. Le Cesne, A; Judson, I; Crowther, D; Rodenhuis, S; Keizer, HJ; Van Hoesel, Q; Blay, JY; Frisch, J; Van Glabbeke, M; Hermans, C; Van Oosterom, A; Tursz, T; Verweij, J
      Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

      JOURNAL OF CLINICAL ONCOLOGY
    9. Judson, I; Kelland, LR
      New developments and approaches in the platinum arena

      DRUGS
    10. Kelland, LR; Giaccone, G; Judson, I
      Questions and answers

      DRUGS
    11. Woll, PJ; Judson, I; Lee, SM; Rodenhuis, S; Nielsen, OS; Buesa, JM; Lorigan, PC; Leyvraz, S; Hermans, C; van Glabbeke, M; Verweij, J
      Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group

      EUROPEAN JOURNAL OF CANCER
    12. Blay, JY; Judson, I; Rodenhuis, S; Hermans, C; Smith, M; van Glabbeke, M; Verweij, J
      Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

      ANTI-CANCER DRUGS
    13. Beale, P; Judson, I; Moore, S; Statkevich, P; Marco, A; Cutler, DL; Reidenberg, P; Brada, M
      Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    14. Brada, M; Judson, I; Beale, P; Moore, S; Reidenberg, P; Statkevich, P; Dugan, M; Batra, V; Cutler, D
      Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

      BRITISH JOURNAL OF CANCER
    15. Twelves, CJ; Gardner, C; Flavin, A; Sludden, J; Dennis, I; de Bono, J; Beale, P; Vasey, P; Hutchison, C; Macham, MA; Rodriguez, A; Judson, I; Bleehen, NM
      Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

      BRITISH JOURNAL OF CANCER
    16. BEALE P; FILSHIE J; JUDSON I
      FREYS-SYNDROME AFTER CISPLATIN-BASED CHEMOTHERAPY FOR TESTICULAR TERATOMA

      Annals of oncology
    17. VANOOSTEROM AT; KRZEMIENLECKI K; NIELSEN OS; JUDSON I; MOURIDSEN HT; SVANCAROVA L; WOLL P; SPOONER D; HERMANS C; VANGLABBEKE M; VERWEIJ J
      FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS)

      Annals of oncology
    18. DIPAOLA ED; JUDSON I; LEE M; RUKA W; BUESA J; COLEMAN R; HERMANS C; VANGLABBEKE M; VERWEIJ J
      PHASE-II RANDOMIZED STUDY COMPARING DOCETAXEL (T) TO DOXORUBICIN (D) IN PREVIOUSLY UNTREATED SOFT-TISSUE SARCOMAS (STS)

      Annals of oncology
    19. BLAY JY; JUDSON I; RODENHUIS S; HERMANS C; SMITH M; VANGLABBEKE M; VERWEIJ J
      A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS

      Annals of oncology
    20. BRIASOULIS E; JUDSON I; PAVLIDIS N; BEALE P; GROOT Y; VEERMAN G; SCHUESSLER M; RAMMOU D; WALKER R; HANAUSKE A
      PHASE-I TRIAL AND PHARMACOKINETICS OF BETA-D-GLUCOSYLISOPHOSPHORAMIDEMUSTARD (D-19575) ADMINISTERED AS A 6-HOUR INFUSION EVERY 3 WEEKS - AN EORTC-ECSG STUDY

      Annals of oncology
    21. REES C; BEALE P; PLUMMER R; HIGHLEY M; CALVERT AH; JUDSON I; SMITH R; HUTCHISON M; AVERBUCH S; MAYNE K
      PHASE-I TRIAL OF ZD9331 GIVEN AS A 30 MINUTE INFUSION ON DAYS 1 AND 8WITH CYCLES REPEATED EVERY 3 WEEKS

      Annals of oncology
    22. WORKMAN P; RAYNAUD F; JUDSON I; KELSON A; TRACY M; LEWIS A; OBAGYE E
      OXYGEN-SENSITIVE REDUCTIVE METABOLISM OF THE FLUORINATED 2-NITROIMIDAZOLE SR-4554 (CRC-94 17) - SUPPORT FOR CLINICAL DEVELOPMENT AS A NONINVASIVE HYPOXIA DETECTION PROBE/

      Annals of oncology
    23. BEALE P; JUDSON I; REES C; TRIGO J; NYHART E; WOLF L; WALKER R; MOORE S; HANWELL J
      PHASE-I TRIAL OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED ORALLY ONCE-DAILY FOR 5 DAYS EVERY 28 DAYS

      Annals of oncology
    24. BEALE P; AHERNE W; JUDSON I; TRIGO J; WOLF L; WALKER R; CROMPTON T; YIN H; MULLIGAN T; JONES D; REIGNER BG
      EXCRETION BALANCE AND PHARMACOKINETIC STUDY OF XELODA(TM) IN CANCER-PATIENTS

      Annals of oncology
    25. BRIASOULIS E; JUDSON I; PAVLIDIS N; BEALE P; WANDERS J; GROOT Y; VEERMAN G; LOCHER M; SCHUESSLER M; TZAMAKOU E; RAMMOU D; WOLF L; WALKER R; HANAUSKE A
      A PHASE-I TRIAL OF D19575, A BETA-D-GLUCOSE-LINKED ISOPHOSPHORAMIDE MUSTARD GIVEN AS A 6-HOUR INFUSION

      Annals of oncology
    26. TRIGO JM; BEALE P; REES C; JUDSON I
      IMPACT OF PHASE-I TRIALS ON THE OUTCOME OF CANCER-PATIENTS - THE INSTITUTE-OF-CANCER-RESEARCH EXPERIENCE

      Annals of oncology
    27. REES C; BEALE P; MITCHELL F; JACKMAN A; SMITH R; MAYNE K; HUTCHISON M; JUDSON I
      PHASE-I TRIAL OF ZD9331, A NON-POLYGLUTAMATABLE THYMIDYLATE SYNTHASE (TS) INHIBITOR GIVEN AS A 5 DAY CONTINUOUS-INFUSION

      Annals of oncology
    28. MITCHELL F; LYNN S; REES C; JUDSON I; CALVERT AH; RATAIN M; DIAB S; ROWINSKY E; MAYNE K; JACKMAN AL
      PLASMA 2'-DEOXYURIDINE (DURD) AS A SURROGATE MARKER OF THYMIDYLATE SYNTHASE (TS) INHIBITION IN PATIENTS IN PHASE-I CLINICAL-TRIALS OF THE TS INHIBITOR ZD9331

      Annals of oncology
    29. PLUMMER R; CALVERT AH; JUDSON I; BEALE P; REES C; GOKAL S; HIGHLEY M; LIND M; SMITH R; HUTCHISON M; MAYNE K
      PHASE-I TRIAL OF ZD9331 GIVEN AS A 30 MINUTE INFUSION ON DAYS 1 AND 8WITH CYCLES REPEATED EVERY 3 WEEKS

      Annals of oncology
    30. BEALE P; RAYNAUD F; HANWELL J; BERRY C; MOORE S; ODELL D; JUDSON I
      PHASE-I STUDY OF ORAL JM216 GIVEN TWICE-DAILY

      Cancer chemotherapy and pharmacology
    31. BEALE P; JUDSON I; HANWELL J; BERRY C; AHERNE W; HICKISH T; MARTIN P; WALKER M
      METABOLISM, EXCRETION AND PHARMACOKINETICS OF A SINGLE-DOSE OF [C-14]-RALTITREXED IN CANCER-PATIENTS

      Cancer chemotherapy and pharmacology
    32. MILLAR BC; MILLAR JL; SHEPHERD V; BLACKWELL P; PORTER H; CUNNINGHAM D; JUDSON I; TRELEAVEN J; POWLES RL; CATOVSKY D
      THE IMPORTANCE OF CD34(+) CD33(-) CELLS IN PLATELET ENGRAFTMENT AFTERINTENSIVE THERAPY FOR CANCER-PATIENTS GIVEN PERIPHERAL-BLOOD STEM-CELL RESCUE/

      Bone marrow transplantation
    33. JUDSON I; MAUGHAN T; BEALE P; PRIMROSE J; HOSKIN P; HANWELL J; BERRY C; WALKERS M; SUTCLIFFE F
      EFFECTS OF IMPAIRED RENAL-FUNCTION ON THE PHARMACOKINETICS OF RALTITREXED (TOMUDEX ZD1694)

      British Journal of Cancer
    34. DEBONO J; BLEEHAN N; SECHER D; BEALE P; MOORE S; SLUDDEN J; DENNIS I; JUDSON I; TWELVES C
      A PHASE-1 STUDY OF XR5000 BY 3HR IV INFUSION

      British Journal of Cancer
    35. FYFE D; REYNAUD F; WHITE J; CLAYTON K; MASON L; GARDNER C; WOLL PJ; JUDSON I; CARMICHAEL J
      A PILOT PHARMACOKINETIC STUDY OF AMSALOG (CI-921) ADMINISTERED ORALLYON A 5 DAY SCHEDULE

      British Journal of Cancer
    36. WEBB A; CUNNINGHAM D; COTTER F; ROSS P; WALTERS J; JUDSON I; RAYNAUD F; CLARKE P; DZIEWANOWSKA ZE
      FIRST DEMONSTRATION OF ANTI-LYMPHOMA ACTIVITY OF BCL-2 ANTISENSE MOLECULE-G3139 - RESULTS OF PHASE I IIA CLINICAL-TRIAL/

      European journal of cancer
    37. JUDSON I; CERNY T; EPELBAUM R; DUNLOP D; SMYTH J; SCHAEFER B; ROELVINK M; KAPLAN S; HANAUSKE A
      PHASE-II TRIAL OF THE ORAL PLATINUM COMPLEX JM216 IN NON-SMALL-CELL LUNG-CANCER - AN EORTC EARLY CLINICAL-STUDIES GROUP INVESTIGATION

      Annals of oncology
    38. LEBEDEV AV; RAYNAUD F; DIZIK M; BECK T; JAEGER JA; BROWN BD; CUNNINGHAM D; WEBB A; MCCAMPBELL E; RILEY T; JUDSON I; WOODLE MC
      ANTI-BCL2 PHOSPHOROTHIOATE G3139 CLINICAL-PHARMACOLOGY - PLASMA-LEVELS DURING CONTINUOUS SUBCUTANEOUS INFUSION BY HPLC ASSAY

      Nucleosides & nucleotides
    39. STATKEVICH P; JUDSON I; CUTLER D; DUGAN M; SALFI M; BATRA V; REIDENBERG P
      EFFECT OF RANITIDINE(R) ON THE PHARMACOKINETICS (PK) OF TEMOZOLOMIDE(T)

      Clinical pharmacology and therapeutics
    40. JUDSON I; BRIASOULIS E; RAYNAUD F; HANWELL J; BERRY C; LACEY H
      PHASE-I TRIAL AND PHARMACOKINETICS OF THE TUBULIN INHIBITOR 1069C85 -A SYNTHETIC AGENT BINDING AT THE COLCHICINE SITE DESIGNED TO OVERCOMEMULTIDRUG-RESISTANCE

      British Journal of Cancer
    41. COTTER F; WEBB A; CUNNINGHAM D; FENNELL D; CORBO M; ROSS P; WALTERS J; JUDSON I; RAYNAUD F; CLARKE P; DZIEWANOWSKA ZE
      ACTIVITY OF BCL-2 ANTISENSE MOLECULE G3139 AGAINST, LYMPHOMA LEUKEMIA- RESULTS FROM A PHASE I/IIA CLINICAL-TRIAL AND FURTHER DEVELOPMENTS/

      Blood
    42. JUDSON I
      MATURITY IN MEDICAL-STUDENTS

      Lancet
    43. REIDENBERG P; STATKEVICH P; JUDSON I; MOORE S; CUTLER D; BATRA V; DUGAN M; BRADA M
      EFFECT OF FOOD ON THE ORAL, BIOAVAILABILITY OF TEMOZOLOMIDE, A NEW CHEMOTHERAPEUTIC AGENT

      Clinical pharmacology and therapeutics
    44. JUDSON I; MCKEAGE M; RAYNAUD F; KELLAND L; HANLEY J; BERRY C; ODELL D; MURRER B; HARRAP K
      THE DEVELOPMENT OF NEW PLATINUM COMPLEXES - ORAL DELIVERY AND NON-CROSS RESISTANCE

      European journal of cancer
    45. COWIE FJ; PINKERTON CR; PHILLIPS M; DICK G; JUDSON I; MCCARTHY PT; FLANAGAN RJ
      CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS

      British Journal of Cancer
    46. VERWEIJ J; JUDSON I; STEWARD W; COLEMAN R; WOOL P; VANPOTTELSBERGHE C; VANGLABBEKE M; MOURIDSEN H
      PHASE-II STUDY OF LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE (MTP PE) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - AN EORTC SOFT-TISSUE-AND-BONE-SARCOMA-GROUP STUDY/

      European journal of cancer
    47. CATIMEL G; VERMORKEN JB; CLAVEL M; DEMULDER P; JUDSON I; SESSA C; PICCART M; BRUNTSCH U; VERWEIJ J; WANDERS J; FRANKLIN H; KAYE SB
      A PHASE-II STUDY OF GEMCITABINE (LY-188011) IN PATIENTS WITH ADVANCEDSQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

      Annals of oncology
    48. JACKMAN A; JUDSON I
      ONCOLOGY DRUG DISCOVERY AND CLINICAL-TRIAL TESTING - WHOS LISTENING

      Cancer investigation
    49. VERRILL M; JUDSON I
      JAUNDICE WITH ONDANSETRON

      Lancet
    50. BLEEHEN NM; CALVERT AH; LEE SM; HARPER P; KAYE SB; JUDSON I; BRAMPTON M
      A CANCER-RESEARCH CAMPAIGN (CRC) PHASE-II TRIAL OF CB10-277 GIVEN BY 24-HOUR INFUSION FOR MALIGNANT-MELANOMA

      British Journal of Cancer
    51. RAYNAUD F; WALTON M; JUDSON I
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE MEASUREMENT OF THE NOVEL MICROTUBULE INHIBITOR 1069C85 IN BIOLOGICAL TISSUES AND FLUIDS

      Journal of chromatography. Biomedical applications
    52. CALVERT H; JUDSON I; VANDERVIJGH WJF
      PLATINUM COMPLEXES IN CANCER MEDICINE - PHARMACOKINETICS AND PHARMACODYNAMICS IN RELATION TO TOXICITY AND THERAPEUTIC ACTIVITY

      Cancer surveys


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/21 alle ore 07:05:56